Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Non-cash Items (2023 - 2026)

InMed Pharmaceuticals has reported Non-cash Items over the past 3 years, most recently at $161372.0 for Q4 2025.

  • For Q4 2025, Non-cash Items rose 17.88% year-over-year to $161372.0; the TTM value through Dec 2025 reached $161372.0, up 17.88%, while the annual FY2025 figure was $72549.0, 60.69% down from the prior year.
  • Non-cash Items for Q4 2025 was $161372.0 at InMed Pharmaceuticals, up from $50055.0 in the prior quarter.
  • Over five years, Non-cash Items peaked at $13.2 million in Q4 2023 and troughed at $42297.0 in Q3 2023.
  • A 3-year average of $2.7 million and a median of $117952.5 in 2024 define the central range for Non-cash Items.
  • Biggest five-year swings in Non-cash Items: soared 86.03% in 2024 and later tumbled 99.25% in 2025.
  • Year by year, Non-cash Items stood at $13.2 million in 2023, then tumbled by 98.96% to $136899.0 in 2024, then grew by 17.88% to $161372.0 in 2025.
  • Business Quant data shows Non-cash Items for INM at $161372.0 in Q4 2025, $50055.0 in Q3 2025, and $72549.0 in Q2 2025.